Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mercè, Ardèvol"'
Autor:
Verónica Saludes, Elisabet Bascuñana, Elena Jordana-Lluch, Sònia Casanovas, Mercè Ardèvol, Esther Soler, Ramón Planas, Vicente Ausina, Elisa Martró
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72600 (2013)
BACKGROUND:Only about 50% of patients chronically infected with HCV genotype 1 (HCV-1) respond to treatment with pegylated interferon-alfa and ribavirin (dual therapy), and protease inhibitors have to be administered together with these drugs increas
Externí odkaz:
https://doaj.org/article/aa3eb4b0235041bfb8ef2e7ac7dc51dc
Autor:
Adolfo Gallego, José A. Carrión, Xavier Torras, Rosa Maria Morillas, E González-Colominas, Sergi Mojal, María-Carlota Londoño, Neus Pagès, Zoe Mariño, Mercè Ardèvol, Ricard Solà, Dulce López, Sabela Lens
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:1100-1107
Background & Aims Drug-drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin (OBV/PTV/r ± DSV ± RBV) are common in clinical trials. Our aim was to analyze the prevalence and manageme
Publikováno v:
Gastroenterología y Hepatología (English Edition). 40:699-708
Interferon-free regimens achieve sustained virologic response (SVR) rates of over 90%, have generally well-tolerated adverse effects and involve 12-week treatment durations for most patients with chronic hepatitis C, including naive or previously tre
Publikováno v:
Gastroenterología y Hepatología. 40:699-708
Interferon-free regimens achieve sustained virologic response (SVR) rates of over 90%, have generally well-tolerated adverse effects and involve 12-week treatment durations for most patients with chronic hepatitis C, including naive or previously tre
Autor:
Verónica Saludes, Maria Alma Bracho, Oliver Valero, Mercè Ardèvol, Ramón Planas, Fernando González-Candelas, Vicente Ausina, Elisa Martró
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e14132 (2010)
Current treatment of chronic hepatitis C virus (HCV) infection has limited efficacy -especially among genotype 1 infected patients-, is costly, and involves severe side effects. Thus, predicting non-response is of major interest for both patient well
Externí odkaz:
https://doaj.org/article/e5ed4f0bd2254fc3bcda80ab51d9afc1
Autor:
Elena, González-Colominas, María-Carlota, Londoño, Rosa M, Morillas, Xavier, Torras, Sergi, Mojal, Sabela, Lens, Dulce, López, Adolfo, Gallego, Zoe, Mariño, Mercè, Ardèvol, Neus, Pagès, Ricard, Solà, Jose A, Carrión
Publikováno v:
Journal of gastroenterology and hepatology. 33(5)
Drug-drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin (OBV/PTV/r ± DSV ± RBV) are common in clinical trials. Our aim was to analyze the prevalence and management of potential DD
Autor:
M. Miquel, F. García, Ricard Navinés, Mercè Ardèvol, J.A. Galeras, Ramon Planas, Rocío Martín-Santos, Ricard Solà, A. Soler, P. Castellví, Crisanto Diez-Quevedo, Helena Masnou
Publikováno v:
Alimentary Pharmacology & Therapeutics. 27:257-265
Summary Background Depression and anxiety have been associated with interferon treatment and low treatment adherence. Aim To study the incidence and associated risk factors of depressive and anxiety disorders during pegylated interferon plus ribaviri
Autor:
Elisabet Bascuñana, Vicente Ausina, Mercè Ardèvol, Ramon Planas, Sònia Casanovas, Elisa Martró, Elena Jordana-Lluch, Esther Soler, Verónica Saludes
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 8, p e72600 (2013)
PLoS ONE, Vol 8, Iss 8, p e72600 (2013)
BACKGROUND:Only about 50% of patients chronically infected with HCV genotype 1 (HCV-1) respond to treatment with pegylated interferon-alfa and ribavirin (dual therapy), and protease inhibitors have to be administered together with these drugs increas
Autor:
Ricard Solà, Ramon Planas, Mercè Ardèvol, Pilar Giner, Crisanto Diez-Quevedo, Rosa Maria Morillas, Joan Costa, D. Giménez, P. Castellví, Moisés Diago, Rocío Martín-Santos, Helena Masnou, Juan Pretel, Ricard Navinés
Publikováno v:
The Journal of clinical psychiatry. 72(4)
BACKGROUND Depression is one of the main reasons for treatment withdrawal and failure in chronic hepatitis C patients treated with interferon. Antidepressants are useful for its treatment, but whether they can also be used for prevention has yet to b